Search the Newsreel

AXS|AXIS Capital Holdings Ltd|Price:116.500|Chg%:+1.920

This article provides a detailed financial overview of AXIS Capital Holdings Ltd (AXS), including its stock performance, market capitalization, P/E ratio, and upcoming earnings date. It presents comprehensive financial statements like the income statement, balance sheet, and cash flow statement, along with key financial …

FDA Acceptance of AXS-12 NDA for Narcolepsy Might Change The Case For Investing In Axsome (AXSM)

Axsome Therapeutics recently received FDA acceptance for its AXS-12 New Drug Application for cataplexy in narcolepsy, with a target action date of May 1, 2027, and no advisory committee planned. This milestone is crucial for Axsome's CNS portfolio, adding a potential orphan indication and …

Entropy Technologies LP Purchases 12,896 Shares of Axis Capital Holdings Limited $AXS

Entropy Technologies LP increased its stake in Axis Capital Holdings Limited by 31.4% in the first quarter, purchasing an additional 12,896 shares, bringing its total holding to 53,905 shares valued at $5.47 million. Axis Capital reported better-than-expected earnings of $3.42 per share but missed …

California Public Employees Retirement System Makes New Investment in Axsome Therapeutics, Inc. $AXSM

The California Public Employees Retirement System (CalPERS) has initiated a new investment in Axsome Therapeutics (NASDAQ:AXSM), acquiring 50,879 shares valued at approximately $8.6 million during the first quarter, representing 0.10% of the company. This comes even as insider selling was noted, with the COO …

TradingKey

This article provides a detailed quarterly and annual income statement for AXIS Capital Holdings Ltd (AXS). It includes extensive financial data such as total revenue, operating expenses, operating profit, net income, and earnings per share, along with year-over-year percentage changes. The content is presented …

Axsome Therapeutics (AXSM) Wins FDA NDA Acceptance, Is The Stock Fully Valued?

Axsome Therapeutics (AXSM) recently received FDA acceptance for its New Drug Application for AXS-12, an investigational treatment for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. Despite a significant 139.02% return over the past year, leading to a current share price …

AXSM|Axsome Therapeutics Inc|Price:241.000|Chg%:-0.530

Axsome Therapeutics Inc (AXSM) is trading at $241.00 with a slight decrease of 0.22%. The company, which specializes in CNS conditions, has strong fundamentals and high growth potential, with an average revenue growth of 135.96% year-on-year over the past three years. Analysts have rated …

Axsome Therapeutics, Inc. (AXSM) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Axsome Therapeutics, Inc. (AXSM), including its current stock price, historical data, financial performance, and analyst ratings. It details the company's biotechnology focus, its commercial products for CNS disorders like Auvelity and Sunosi, and its pipeline of …

First Trust Advisors LP Increases Position in Axsome Therapeutics, Inc. $AXSM

First Trust Advisors LP significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 1,230.2% in the first quarter, now owning 577,479 shares valued at $97.6 million. Despite missing EPS estimates, Axsome's revenue grew 57.4% year-over-year. Analysts maintain a "Moderate Buy" rating with an average …

Axis Capital Holdings Limited Revenue Breakdown – NYSE:AXS

Axsome Therapeutics, Inc. Revenue Breakdown – NASDAQ:AXSM

This article provides a revenue breakdown for Axsome Therapeutics, Inc. (NASDAQ: AXSM). It highlights that the company generated $633.80 million USD last year, with its "Novel Therapies for the Management of Central Nervous System Disorders" segment contributing the most at $638.50 million USD. The …

AXIS Capital (AXS) Stock Still Looks Cheap After A 161% Run

Despite a 161% return over the past five years, AXIS Capital Holdings (AXS) appears undervalued according to Simply Wall St's analysis. The stock trades at a lower P/E ratio (8.1x) compared to the industry average (12.2x) and its peer group (10.7x), suggesting a potential …

Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug

Is AXIS Capital Holdings (AXS) Undervalued As Earnings Optimism Builds?

Analysts are optimistic about AXIS Capital Holdings (AXS) outpacing Q2 2026 earnings estimates, with the stock showing strong price performance over recent periods. Despite a solid performance, the company is considered approximately 9.9% undervalued according to narrative-based fair value assessments, primarily due to a …

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12, a treatment for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting, which could indicate a …

AXSOME THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $265 FROM $250

Leerink Partners has raised its target price for Axsome Therapeutics Inc. (AXSM) to $265 from $250. This change suggests an increased positive outlook from the financial institution regarding the company's future performance. The article is very brief and does not provide further details on …

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets

BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year-over-year. The stock opened at …

Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research

Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a "hold" to a "strong sell" rating. This comes despite a broader "Moderate Buy" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.26 missing …

AXSM Initiated Coverage by BMO Capital -- Outperform Rating Assi

BMO Capital has initiated coverage on Axsome Therapeutics (AXSM) with an Outperform rating and a price target of $310.00. While GuruFocus indicates the stock is 2.1% undervalued with a GF Value™ of $226.26, its GF Score™ of 52/100 points to average performance, burdened by …

Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides

Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, …

Axis Capital (AXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Axis Capital (AXS) is expected to beat Q2 earnings estimates, with analysts predicting $3.23 EPS and $1.72 billion in revenue. The company has a Zacks Earnings ESP of +3.82% and a Zacks Rank of #3, indicating a high probability of exceeding consensus EPS. This …

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the initiation of …

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts

Axsome Therapeutics (NASDAQ:AXSM) has received a "Moderate Buy" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a larger-than-expected loss of $1.26 per share, …

Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.5% in the first quarter, though it still holds a significant position. Axsome Therapeutics reported mixed quarterly results, beating revenue expectations but missing on earnings per share. Despite the mixed results and …

Axsome gains as narcolepsy therapy undergoes FDA review

Axsome Therapeutics' stock rose after the FDA accepted its New Drug Application for solriamfetol for narcolepsy, setting a PDUFA date for February 12, 2026. The therapy has shown promise in improving wakefulness and reducing excessive daytime sleepiness in narcolepsy patients. This marks a positive …

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Three analysts have issued bullish sentiments on several healthcare companies. Andrew Tsai from Jefferies maintained a Buy rating on Axsome Therapeutics with a $380.00 price target, while Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings with a $45.00 price target. …

Responsive Playbooks and the AXSM Inflection

This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting weak near-term sentiment but strong long-term potential. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and details multi-timeframe signal analysis with specific support and resistance levels. The analysis …

Axsome's AXS-12 Advances to FDA Review for Cataplexy

The FDA has accepted Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy, setting a PDUFA target action date of May 1, 2027. AXS-12 aims to be a non-scheduled, orally dosed option for daytime use, distinct …

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy

Axsome Therapeutics (AXSM) has received FDA acceptance for its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy patients, with a target decision date set and no advisory committee meeting planned. This regulatory milestone provides increased visibility for investors, potentially expanding …

Axsome FDA application accepted for 2027 target date

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy. This acceptance sets a formal target action date of May 1, 2027, for the drug, which is designed to address the sudden loss …

Axsome gets FDA filing acceptance for narcolepsy drug AXS-12

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy patients, setting a target action date of May 1, 2027. The drug, which has Orphan Drug Designation, targets the sudden muscle tone loss …

Axsome gains FDA review for narcolepsy therapy (AXSM:NASDAQ)

Axsome Therapeutics' shares rose in premarket trading after the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for narcolepsy. This marks a significant step for the neurology drug developer in bringing its treatment to market.

FDA accepts Axsome Therapeutics (NASDAQ: AXSM) AXS-12 narcolepsy NDA

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, and does not …

Axsome Therapeutics Announces FDA Acceptance of NDA for AXS-12 in Narcolepsy Cataplexy; PDUFA Date Set for May 1, 2027

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting for …

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for treating cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting for …

Axsome’s 60% quarter pauses with a 127% Fair Value premium and lighter volume

AXSM slipped 1.8% for the week but remains only 3.7% below its 52-week high, leaving a constructive trend intact while confirmation has become less forceful.